Bengaluru-based biopharmaceutical company Syngene International is all set to raise Rs 550 crore through an initial public offer (IPO). The price band for each equity share has been set at Rs 240-250. The issue will open on July 27 and close on July 29. This IPO is an offer for sale, meaning the money raised goes to the selling shareholders, not the company.
The equity shares will be listed on the NSE and the BSE. The book running lead managers to the issue are Axis Capital, Credit Suisse Securities (India), Jefferies India and Karvy Computershare.
Incorporated in 1993, Syngene International Ltd is a subsidiary of Biocon, a global biopharmaceutical enterprise focused on delivering affordable formulations and compounds. Syngene offer customized models as per their clients’ requirements. These range from a full-time equivalent (FTE) to a fee-for-service (FFS) model, or a combination thereof.
| Company Name | CMP |
|---|---|
| Syngene Internation. | 435.70 |
| Indegene | 486.80 |
| CMS Info Systems | 318.00 |
| JITF Infralogistics | 338.00 |
| Sagility | 42.95 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: